Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04599699
Other study ID # Changhai Hospi
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2020
Est. completion date May 1, 2023

Study information

Verified date October 2020
Source Changhai Hospital
Contact Huojun Zhang, PhD
Phone 021-31162222
Email chyyzhj@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to test the safety and efficacy of integrated boost to the dominant intraprostatic nodule based on Ga-68 Prostate-Specific Membrane Antigen (PSMA) PET/MR in Stereotactic Body Radiation Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is the irradiation of the entire prostate gland with or without seminal vesicles accompanied or not by hormonal therapy.


Description:

Radiotherapy is considered standard of care treatment for prostate cancer. In light of the accumulating clinical evidence favoring the use of hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and highly efficient outpatient therapy. Although the proposed extreme hypofractionated radiotherapy approach was expected to provide excellent local control of the primary prostate cancer, a proportion of patients with intermediate- or high-risk disease may have recurrences with local recurrence or distant metastasis in the future, requiring strategies to minimize systemic disease. Ga-68 PSMA PET/MR has high accuracy in the diagnosis and staging of prostate cancer. In this protocol, pretreatment Ga-68 PSMA PET/MR and CT scanning were performed in all patients as well as the imaging fusion before delineating the target. This study would explore the simultaneously integrated boost or equential integrated boost to the dominant intraprostatic nodule based on Ga-68 PSMA PET/MR in SBRT.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 1, 2023
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate - tumor clinical stage cT1-3N0M0 according to AJCC TNM 2017 - Without any treatment of prostate cancer including radiotherapy, ADT, chemotherapy, focal treatment, etc. - With the examination of Ga-68 PSMA PET/MR - International Prostate Symptom Score(IPSS)<15 (alpha blockers allowed), without severe urethral obstruction symptoms - ECOG performance status 0-2 - Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures Exclusion Criteria: - Prior pelvic RT - A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI - Tumor clinical stage cT4, with metastases including bone, lymph nodes or organ metastasis - Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate - Severe or active co-morbidity likely to impact on the advisability of SBRT like severe liver or kidney dysfunction, etc. - Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, etc. - Patients who have participated in other clinical trials for less than three months - Patients have acute prostatitis or chronic prostatitis with urinary symptoms - Urine routine indicates obvious urinary system infection and no significant improvement after anti-infective treatment, or conversion to recurrent urinary system infection - Unsuitable to participate in this clinical trial judged by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Stereotactic Body Radiation Therapy (SBRT)
Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.

Locations

Country Name City State
China Shanghai Changhai Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Probability of Acute genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction Acute genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) (grade 2 or more) according to the NCI CTCAE v4.0. 90 days after the first fraction of radiotherapy treatment
Secondary The Probability of Chronic genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) Chronic genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) (grade 2 or more) according to the NCI CTCAE v4.0. > 90 days and up to 3 years from the start of protocol treatment
Secondary 1-year Biochemical Progression-free Survival (bPFS) Biochemical Progression-free Survival (bPFS) Assessment at 1-year
Secondary 1-year Local Progression-Free-Survival(LPFS) Local Progression-Free-Survival(LPFS) Assessment at 1-year
Secondary 1-year Distant Metastasis Free Survival(DMFS) Distant Metastasis Free Survival(DMFS) Assessment at 1-year
Secondary 1-year Overall Survival (OS) Overall Survival (OS) Assessment at 1-year
See also
  Status Clinical Trial Phase
Recruiting NCT05243134 - The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Completed NCT02486874 - Clinical Evaluation of PoreSkin Phase 1
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Recruiting NCT04599686 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer N/A
Recruiting NCT03351842 - Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% Phase 2
Completed NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Completed NCT03439930 - The Effect of Balance Training on Neuromuscular Control in Subjects With CAI N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Recruiting NCT02971982 - PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT02820272 - Water for Reducing Pain in Negative Pressure Wound Therapy Phase 2
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 Phase 4
Completed NCT00164307 - Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Phase 1/Phase 2
Completed NCT00164528 - Intervening With Children/Adolescents With FAS/ARND Phase 1/Phase 2
Recruiting NCT04603586 - Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses N/A
Recruiting NCT03375424 - Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany N/A
Not yet recruiting NCT04062370 - Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Phase 4
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Completed NCT04661228 - Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
Recruiting NCT03365141 - Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo N/A